Skip to main content

Table 1 Demographic characteristics of patients with combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma, and cholangiocarcinoma

From: Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis

Characteristics Total (n = 505) cHCC-CC (n = 35) HCC (n = 419) CC (n = 51) p value
Male 404 (80.0) 28 (80.0) 343 (81.9)b 33 (64.7) 0.015
Age (years) 61 (32–87) 57 (37–79)a 62 (32–87) 60 (33–85) 0.211
Hypertension 208 (41.2) 16 (45.7) 178 (42.5)b 14 (27.5) 0.102
Diabetes Mellitus 119 (23.60 3 (8.6)a 102 (24.3) 14 (27.5)c 0.085
Smoking 208 (48.6) 27 (47.4) 87 (20.8) 8 (15.7) 0.695
Alcohol use 102 (20.2) 7 (20.0) 74 (17.7) 4 (7.8)c 0.043
HBV positive 227 (45.0) 15 (42.9) 186 (44.4) 26 (51.0) 0.649
HCV positive 124 (24.6) 8 (22.9) 98 (23.9) 18 (35.3) 0.171
Total Bilirubin 0.95 ± 0.42 0.93 ± 0.32 0.95 ± 0.42 0.94 ± 0.46 0.982
Albumin 4.1 ± 0.3 4.0 ± 0.3 4.1 ± 0.3 4.2 ± 0.2 0.308
INR 1.04 ± 0.07 1.03 ± 0.04 1.04 ± 0.07 1.05 ± 0.12 0.451
Cirrhosis 163 (32.3) 12 (34.4) 145 (34.6)b 6 (11.8)c 0.004
Child–Pugh class A 489 (96.8) 35 (100) 403 (96.5) 51 (100) 0.399
Edmondson–Steiner Grades, I–II 322 (63.7) 18 (51.4) 292 (69.6)b 12 (23.5) 0.404
Tumor size 5.3 ± 3.3 5.8 ± 2.1 5.2 ± 3.4 5.3 ± 2.4 0.623
Tumor size ≥ 5 cm 225 (45.2) 24 (68.6)a 178 (42.5)b 23 (52.3) 0.007
Tumor number (≥ 2) 51 (10.2) 3 (8.6) 46 (11.0) 2 (4.5) 0.385
AFP (ng/mL) ≥ 200 91(21.3) 8 (22.9) 115 (27.4)b 3 (5.9)c 0.003
ICG% 11.1 ± 7.9 10.7 ± 5.5 11.3 ± 8.3 9.6 ± 5.5 0.359
Operative margin > 1 cm 361 (71.4) 25 (71.4) 306 (73.0)b 30 (58.8)c 0.003
Major hepatectomy 257 (50.8) 19 (54.2) 203 (48.4)b 35 (68.6)c 0.007
Microvascular invasion 152 (30.1) 13 (37.1) 131 (31.3)b 8 (15.7)c 0.047
Macrovascular invasion 72 (14.3) 5 (14.3) 66 (15.8)b 1 (2.0)c 0.029
Lympho nodules metastasis 20 (4.0) 7 (20.2)a 5 (1.2)b 8 (15.7) < 0.0001
Distal metastasis 10 (2.0) 0 (0) 7 (1.7)b 3 (5.9) 0.086
AJCC stage, I–II 383 (75.8) 27 (77.1) 320 (76.3)b 36 (70.5) < 0.0001
Antiviral therapy 282 (55.8) 18 (51.4) 239 (57.0) 25 (49.0) 0.168
Recurrence 135 (26.7) 9 (25.7) 120 (28.6)b 6 (11.8) 0.036
Recurrence per 100 person-years 33.7 42.1 38.5b 25.3 < 0.0001
Mortality 149 (29.5) 14 (40.0)a 108 (25.8)b 27 (52.8) < 0.0001
Mortality per 100 person-years 94.1 104.1a 86.7b 113.8 < 0.0001
Follow-up times (months) 38 (1–94) 31 (4–75)a 40 (1–94)b 26 (1–85) < 0.0001
  1. Data are presented as the median (range) or number (percentage).
  2. HBV Hepatitis B virus, HCV Hepatitis C virus, INR international normalized ratio, AFP alpha-fetoprotein, ICG indocyanine green, AJCC American Joint Committee on Cancer
  3. ap < 0.05, cHCC-CC versus HCC
  4. bp < 0.05, cHCC-CC versus CC
  5. cp < 0.05, HCC versus CC